[Form 4] ResMed Inc. Insider Trading Activity

Rhea-AI Filing Summary

ResMed Inc. (RMD) – Form 4 Insider Transaction

CEO Michael J. Farrell exercised 8,009 stock options at an exercise price of $101.64 on 07/07/2025 and immediately sold the same number of common shares at a weighted-average price of $256.7207 under a Rule 10b5-1 plan adopted 10/31/2024. After the transaction, Farrell directly owns 455,503 common shares and 32,038 remaining options. The sale represents roughly 1.7 % of his direct equity holdings, leaving the vast majority of his ownership intact.

No additional derivative positions were created or disposed of, and no other insiders participated. The filing conveys routine portfolio management rather than a strategic shift in insider sentiment.

Positive

• CEO retains 455,503 shares, demonstrating continued long-term alignment with shareholders despite partial liquidation.

Negative

• Insider sale of 8,009 shares may be viewed cautiously by some investors, although magnitude is small (<2 % of holdings).

Insights

Securities Analyst

TL;DR: Small CEO sale, negligible impact on RMD valuation.

The 8,009-share sale generates a pre-tax spread of roughly $1.24 million, but the CEO retains ~455k shares, maintaining strong alignment with shareholders. Transaction size (<2 % of holdings) and pre-planned 10b5-1 status lower signaling value. I view the event as neutral for the investment thesis and would not adjust earnings or multiple assumptions.

Corporate Governance Expert

TL;DR: Routine 10b5-1 trade; governance risk unchanged.

The sale was executed under a disclosed 10b5-1 plan, reducing concerns about timing or material-non-public information. Farrell’s remaining stake (~$117 million at current prices) continues to align his incentives with long-term performance. No red flags emerge from this filing.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Farrell Michael J.

(Last) (First) (Middle)

RESMED INC.

9001 SPECTRUM CENTER BLVD

(Street)

SAN DIEGO CA 92123

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
RESMED INC [ RMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
07/07/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
ResMed Common Stock	07/07/2025		M(1)		8,009	A	$101.64	463,512	D
ResMed Common Stock	07/07/2025		S(1)		8,009	D	$256.7207(2)	455,503	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
ResMed Common Stock Options	$101.64	07/07/2025		M			8,009	11/11/2019(3)	11/14/2025	ResMed Common Stock	8,009	$0	32,038	D

Explanation of Responses:

1. The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024.

2. This transaction was executed in multiple trades at prices ranging from $255.6 - $258.22. The price reported above reflects the weighted average sale price.

3. Represents date options first become exercisable. Options vest 1/3 per year.

	Michael J. Farrell, Chief Executive Officer	07/08/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many ResMed (RMD) shares did the CEO sell?

Michael J. Farrell sold 8,009 common shares on 07/07/2025.

What price did the ResMed shares sell for?

The weighted-average sale price was $256.7207 per share, with trades ranging from $255.60 to $258.22.

Was the transaction pre-arranged under Rule 10b5-1?

Yes. The Form 4 states the trade was executed under a 10b5-1 plan adopted on 10/31/2024.

How many ResMed shares does the CEO still own?

After the transaction, Farrell directly owns 455,503 common shares plus 32,038 options.

Does the sale signal negative insider sentiment?

Given the small size (<2 % of holdings) and 10b5-1 status, most analysts view the impact as neutral.